Gamma-irradiated rotavirus: A possible whole virus inactivated vaccine

PLoS One. 2018 Jun 7;13(6):e0198182. doi: 10.1371/journal.pone.0198182. eCollection 2018.

Abstract

Rotavirus (RV) causes significant morbidity and mortality in developing countries, where children and infants are highly susceptible to severe disease symptoms. While live attenuated vaccines are available, reduced vaccine efficacy in developing countries illustrates the need for highly immunogenic alternative vaccines. Here, we studied the possible inactivation of RV using gamma(γ)-irradiation, and assessed the sterility and immunogenicity of γ-irradiated RV (γ-RV) as a novel vaccine candidate. Interestingly, the inactivation curve of RV did not show a log-linear regression following exposure to increased doses of γ-rays, and consequently the radiation dose required to achieve the internationally accepted Sterility Assurance Level could not be calculated. Nonetheless, we performed sterility testing based on serial passages of γ-RV, and our data clearly illustrate the lack of infectivity of γ-RV preparations irradiated with 50 kGy. In addition, we tested the immunogenicity of 50 kGy γ-RV in mice and our data illustrate the induction of strong RV-specific neutralising antibody responses following administration of γ-RV without using adjuvant. Therefore, whilst γ-RV may not constitute a replacement for current RV vaccines, this study represents a proof-of-concept that γ-irradiation can be applied to inactivate RV for vaccine purposes. Further investigation will be required to address whether γ-irradiation can be applied to improve safety and efficacy of existing live attenuated vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Chlorocebus aethiops
  • Female
  • Gamma Rays*
  • Immunogenicity, Vaccine / radiation effects
  • Mice
  • Mice, Inbred C57BL
  • Rotavirus / radiation effects*
  • Rotavirus Infections / immunology
  • Rotavirus Infections / prevention & control*
  • Rotavirus Vaccines* / immunology
  • Rotavirus Vaccines* / therapeutic use
  • Vaccines, Inactivated* / therapeutic use
  • Vero Cells
  • Virus Inactivation / radiation effects*

Substances

  • Rotavirus Vaccines
  • Vaccines, Inactivated

Grants and funding

Gamma-irradiation performed at ANSTO (Lucas Heights, New South Wales), supported by an Australian Institute of Nuclear Science and Engineering (AINSE) Research Award (ALNGRA15517; awarded to MA). The authors have no conflicting financial interests. MA is head of the vaccine research group at the University of Adelaide and the Chief Scientific Officer of Gamma Vaccines Pty Ltd. TRH is an affiliated professor at the University of Adelaide and the Executive Chairman of Gamma Vaccines Pty Ltd. This does not alter adherence to policies on sharing data and materials. Gamma Vaccines Pty Ltd has no role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.